We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

PTAB Axes 2 Patents On Insulin Drug Lantus

Law360 (December 13, 2018, 4:39 PM EST) -- The Patent Trial and Appeal Board on Wednesday invalidated two Sanofi-Aventis Deutschland GmbH patents for the insulin medication Lantus, while calling evidence of the success of the multibillion-dollar drug “weak” because...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.